When does Eliquis’ patent protection end?
Eliquis (apixaban) has multiple layers of patent protection and regulatory exclusivities, so there is no single “the patent is up on one date” answer. The effective end date depends on which specific Eliquis patent is being referenced (drug substance, formulation, specific dosing/regimen claims, or manufacturing process).
DrugPatentWatch tracks Eliquis patent status and projected “patent expiry” timelines across the relevant patents. Checking the Eliquis page there is the fastest way to see the latest, patent-by-patent expiry estimates: DrugPatentWatch – Eliquis.
How long is the exclusivity “gap” after a first patent expires?
Even if one Eliquis patent expires, other patents or exclusivity protections can still block generic or biosimilar competition for the full product. That’s why Eliquis often has staggered patent expirations rather than one clean cutoff date, and why “patent up” timing varies depending on which patent is the bottleneck for approval.
What should you look for on Eliquis patent listings?
Patent expiry trackers like DrugPatentWatch typically break things down into different patent families or claim types. For “when can competitors launch,” the most relevant entries are usually the ones labeled as:
- formulation/device (if applicable),
- specific manufacturing or process patents, and
- any “key” patents tied to the exact marketed drug.
Those are the entries that tend to matter for whether an abbreviated pathway (for generics) or other filings can proceed.
Which country matters for the expiry date?
Patent protection is jurisdiction-specific. “When is Eliquis’ patent up” can differ between the U.S., EU/UK, and other markets because patent filings and enforcement dates differ by country. If you tell me which country (U.S. vs EU/UK vs another), I can narrow the answer to the most relevant timelines shown on the tracker.
Source
- DrugPatentWatch – Eliquis